India Rupee Plunge Boon For Most Domestic Pharma Firms, But Gains May Be Delayed
This article was originally published in PharmAsia News
Executive Summary
The Indian rupee has played havoc with the country’s macroeconomic fundamentals and like in emerging markets such as Turkey, Brazil and Indonesia caused policymakers to carefully eye capital flows. But India’s unique position as a major drug manufacturer and exporter gives many of its companies the prospect of higher domestic earnings as sales are widely priced in dollars.